Obexelimab + Placebo
Phase 2Active 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsing Multiple Sclerosis
Conditions
Relapsing Multiple Sclerosis
Trial Timeline
Aug 26, 2024 → Feb 1, 2026
NCT ID
NCT06564311About Obexelimab + Placebo
Obexelimab + Placebo is a phase 2 stage product being developed by Zenas BioPharma for Relapsing Multiple Sclerosis. The current trial status is active. This product is registered under clinical trial identifier NCT06564311. Target conditions include Relapsing Multiple Sclerosis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06559163 | Phase 2 | Recruiting |
| NCT06564311 | Phase 2 | Active |
Competing Products
20 competing products in Relapsing Multiple Sclerosis